Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Erie Regional Cancer Center
mi
from
Erie, PA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Erie Regional Cancer Center
mi
from
Erie, PA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Cancer Center - Sherman
mi
from
Sherman, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Alabama Oncology
mi
from
Birmingham, AL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Alabama Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
St. Mary's Hospital Regional Cancer Center
mi
from
Grand Junction, CO
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
St. Mary's Hospital Regional Cancer Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
West Ky Hematology Oncology Group Psc
mi
from
Paducah, KY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
West Ky Hematology Oncology Group Psc
mi
from
Paducah, KY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Bay Hematology Oncology
mi
from
Easton, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Bay Hematology Oncology
mi
from
Easton, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Forrest General Cancer Center
mi
from
Hattiesburg, MS
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Forrest General Cancer Center
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Glens Falls Hospital
mi
from
Glens Falls, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cancer Care Northwest
mi
from
Spokane Valley, WA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cancer Care Northwest
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
St. Joseph Heritage Medical Group
mi
from
Fullerton, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
St. Joseph Heritage Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
East Jefferson General Hospital
mi
from
Metairie, LA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
East Jefferson General Hospital
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Saint Vincent Frontier Cancer Center
mi
from
Billings, MT
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Saint Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
San Juan Oncology Associates
mi
from
Farmington, NM
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
San Juan Oncology Associates
mi
from
Farmington, NM
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
St. Luke'S University Hospital Bethlehem
mi
from
Bethlehem, PA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
St. Luke'S University Hospital Bethlehem
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology
mi
from
El Paso, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Providence Regional Cancer Partnership
mi
from
Everett, WA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Central Coast Medical Oncology
mi
from
Santa Maria, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Central Coast Medical Oncology
mi
from
Santa Maria, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Rocky Mountain Cancer Centers
mi
from
Lakewood, CO
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Rocky Mountain Cancer Centers
mi
from
Lakewood, CO
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Eastern Ct Hem Onc Assoc
mi
from
Norwich, CT
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Eastern Ct Hem Onc Assoc
mi
from
Norwich, CT
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
First Health of the Carolinas
mi
from
Pinehurst, NC
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
First Health of the Carolinas
mi
from
Pinehurst, NC
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Oncology Hematology Care
mi
from
Cincinnati, OH
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Oklahoma Cancer Specialists and Research Institute, LLC
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Lehigh Valley Hospital
mi
from
Allentown, PA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
West Cancer Center
mi
from
Germantown, TN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
West Cancer Center
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
White Plains Hospital
mi
from
White Plains, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
White Plains Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Sanford Health
mi
from
Sioux Falls, SD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
The Stamford Hospital
mi
from
Stamford, CT
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
The Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Va Ct Healthcare System
mi
from
West Haven, CT
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Va Ct Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Tallahassee Memorial Cancer Center
mi
from
Tallahassee, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Tallahassee Memorial Cancer Center
mi
from
Tallahassee, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
University Cancer and Blood Center LLC
mi
from
Athens, GA
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
University of Maryland
mi
from
Baltimore, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Minnesota Oncology Hematology, PA
mi
from
Edina, MN
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Minnesota Oncology Hematology, PA
mi
from
Edina, MN
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Columbia University Medical Center (Cumc)
mi
from
New York, NY
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Columbia University Medical Center (Cumc)
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Florida Cancer Specialists S.
mi
from
Fort Myers, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Florida Cancer Specialists S.
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated:  5/1/2018
Baptist Health Medical Group Oncology, LLC
mi
from
Miami, FL
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
Status: Enrolling
Updated: 5/1/2018
Baptist Health Medical Group Oncology, LLC
mi
from
Miami, FL
Click here to add this to my saved trials